Seropersistence of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine): 6-month follow-up of a randomized, controlled, observer-blind, phase 2/3 immuno-bridging study in Indian adults by Prasad S. Kulkarni, Chandrasekaran Padmapriyadarsini, Johan Vekemans, Ashish Bavdekar, Madhu Gupta, Praveen Kulkarni, B.S. Garg, Nithya J. Gogtay, Muralidhar Tambe, Sanjay Lalwani, Kiranjit Singh, Renuka Munshi, Sushant Meshram, T.S. Selvavinayagam, Krishna Pandey, Devi Madhavi Bhimarasetty, S.R. Ramakrishnan, Chetanraj Bhamare, Abhijeet Dharmadhikari, Chandrashekhar Budhawant, Cyrille J. Bonhomme, Madhuri Thakar, Swarali N. Kurle, Elizabeth J. Kelly, Manish Gautam, Nivedita Gupta, Samiran Panda, Balram Bhargava, Cyrus S. Poonawalla, Umesh Shaligram, Dhananjay Kapse, Bhagwat Gunale

Get full text

Immunogenicity and Safety of ChAdOx1 nCoV-19 (AZD1222) as a Homologous Fourth-Dose Booster: A Substudy of the Phase 3 COV003 Trial in Brazil by Sue Ann Costa Clemens, MD, PhD, Sagida Bibi, PhD, Natalie G. Marchevsky, MSc, Parvinder K. Aley, PhD, Federica Cappuccini, PhD, Sophie A. Davies, BSc, Isabela Gonzalez, PhD, Sarah C. Kelly, MSc, Yama F. Mujadidi, MSc, Eveline Pipolo Milan, MD, PhD, Alexandre V. Schwarzbold, PhD, Eduardo Sprinz, MD, DSc, Merryn Voysey, DPhil, Lily Y. Weckx, MD, PhD, Daniel Wright, DPhil, Himanshu Bansal, MS, Maria A.S. Bergagård, MSc, Abby J. Isaacs, MS, Elizabeth J. Kelly, PhD, Dongmei Lan, MS, Shethah Morgan, PhD, Nirmal Kumar Shankar, BAMS, Kathryn Shoemaker, MS, Tonya L. Villafana, PhD, Teresa Lambe, PhD, Justin A. Green, MD, PhD, Andrew J. Pollard, FMedSci

Get full text